G1 Therapeutics (GTHX)
(Delayed Data from NSDQ)
$3.30 USD
-0.01 (-0.30%)
Updated May 31, 2024 04:00 PM ET
After-Market: $3.31 +0.01 (0.30%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
G1 Therapeutics [GTHX]
Reports for Purchase
Showing records 341 - 351 ( 351 total )
Company: G1 Therapeutics
Industry: Unclassified
Company: G1 Therapeutics
Industry: Unclassified
Trilaciclib Successful in 1L SCLC, De-Risking Ph 2 Programs
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Unclassified
Company: G1 Therapeutics
Industry: Unclassified
Company: G1 Therapeutics
Industry: Unclassified
Top Picks for 2018
Provider: WEDBUSH SECURITIES INC.
Company: G1 Therapeutics
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: G1 Therapeutics
Industry: Unclassified
3Q, Key Data Readouts Coming Up in Early 2018
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Unclassified
HEALTHCARE - 2017 PacGrow Healthcare Conference: Day 1 Recap
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Unclassified
Q2; Pipeline Mostly on Track; Looking Ahead to 2018 for Key Trilaciclib Updates
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: G1 Therapeutics
Industry: Unclassified
Initiating Coverage with an OUTPERFORM and $31PT: Stopping the Cycle of Bad Drugs
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D